Bystander target cell lysis and cytokine production by dengue virus- specific human CD4+ cytotoxic T-lymphocyte clones

Journal of Virology

Volumn 73, Issue 5, 1999, Pages 3623-3629

  Gagnon, Susan J ^a   Ennis, Francis A ^a   Rothman, Alan L ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAMMA INTERFERON; LYMPHOTOXIN; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; DENGUE VIRUS; HELPER CELL; HUMAN; HUMAN CELL; LYMPHOCYTE CLONE; PRIORITY JOURNAL; TARGET CELL DESTRUCTION;

EID: 0032930732     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.73.5.3623-3629.1999     Document Type: Article

References (50)

1. Ando, K., K. Hiroishi, T. Kaneko, T. Moriyama, Y. Muto, N. Kayagaki, H. Yagita, K. Okumura, and M. Imawari. 1997. Perforin, Fas/Fas ligand, and TNF-α pathways as specific and bystander killing mechanisms of hepatitis C virus-specific human CTL. J. Immunol. 158:5283-5291.
2. + surface phenotype and a T helper type 1 profile of cytokine secretion in the liver of patients chronically infected with hepatitis B virus. J. Immunol. 152:3074-3087.
3. Bhamarapravati, N., P. Tuchinda, and V. Boonyapaknavik. 1967. Pathology of Thailand haemorrhagic fever: a study of 100 autopsy cases. Ann. Trop. Med. Parasitol. 61:500-510.
4. Bouma, M.-E., E. Rogier, N. Verthier, C. Labarre, and G. Feldmann. 1989. Further cellular investigation of the human hepatoblastoma-erived cell line HepG2: morphology and immunocytochemical studies of hepatic-secreted proteins. In Vitro Cell. Dev. Biol. 25:267-275.
5. Cruikshank, S. M., J. Southgate, P. J. Selby, and L. K. Trejdosiewicz. 1998. Expression and cytokine regulation of immune recognition elements by normal human biliary epithelial and established liver cell lines in vitro. J. Hepatol. 29:550-558.
6. + T-cell clones specifically activated by IE1 peptides in vitro. J. Virol. 70:2162-2169.
7. + cytotoxic T-lymphocyte clones. J. Virol. 70:141-147.
8. Galle, P. R., W. J. Hofmann, H. Walczak, H. Schaller, G. Otto, W. Stremmel, P. H. Krammer, and L. Runkel. 1995. Involvement of the CD95 (APO-1/ Fas) receptor and ligand in liver damage. J. Exp. Med. 182:1223-1230.
9. Hall, W. C., T. P. Crowell, D. M. Watts, V. L. R. Barros, H. Kruger, F. Pinheiro, and C. J. Peters. 1991. Demonstration of yellow fever and dengue antigens in formalin-fixed paraffin-embedded human liver by immunohistochemical analysis. Am. J. Trop. Med. Hyg. 45:408-417.
10. Halstead, S. B. 1988. Pathogenesis of dengue: challenges to molecular biology. Science 239:476-481.
11. Hargreaves, R. G., N. J. Borthwick, M. S. Montani, E. Piccolella, P. Carmichael, R. I. Lechler, A. N. Akbar, and G. Lombardi. 1997. Dissociation of T cell anergy from apoptosis by blockade of Fas/Apo-1 (CD95) signaling. J. Immunol. 158:3099-3107.
12. Hiramatsu, N., N. Hayashi, K. Katayama, K. Mochizuki, Y. Kawanishi, A. Kasahara, H. Fusamoto, and T. Kamada. 1994. Immunohistochemical detection of Fas antigen in liver tissues of patients with chronic hepatitis C. Hepatology 19:1354-1359.
13. Hober, D., L. Poli, B. Roblin, P. Gestas, E. Chungue, G. Granic, P. Imbert, J.-L. Pecarere, R. Vergez-Pascal, P. Wattre, and M. Maniez-Montreuil. 1993. Serum levels of tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and interleukin-1β (IL-1β) in dengue-infected patients. Am. J. Trop. Med. Hyg. 48:324-331.
14. Horvath, C. J., T. J. Ferro, G. Jesmok, and A. Malik. 1988. Recombinant tumor necrosis factor increases pulmonary vascular permeability independent of neutrophils. Proc. Natl. Acad. Sci. USA 85:9219-9223.
15. Innis, B. L., K. S. A. Myint, A. Nisalak, K. G. Ishak, S. Nimmannitya, T. Laohapand, S. Tanprasertsuk, V. Pongritsakada, and U. Thisyakorn. 1990. Acute liver failure is one important cause of fatal dengue infection (abstr). Southeast Asian J. Trop. Med. Public Health 21:695-696.
16. + human cytotoxic T-cell clones are restricted by class II HLA antigens. J. Immunol. 133:754-757.
17. Jassoy, C., T. Harrer, T. Rosenthal, B. A. Navia, J. Worth, P. R. Johnson, and B. D. Walker. 1993. Human immunodeficiency virus type 1-specific cytotoxic T lymphocytes release gamma interferon, tumor necrosis factor alpha (TNF-α), and TNF-β when they encounter their target antigens. J. Virol. 67:2844-2852.
18. + cytotoxic T cells. Proc. Natl. Acad. Sci. 91:4185-4189.
19. Kalayanarooj, S., D. W. Vaughn, S. Nimmannitya, S. Green, S. Suntayakorn, N. Kunentrasai, W. Viramitrachai, S. Ratanachu-eke, S. Kiatpolpoj, B. L. Innis, A. L. Rothman, A. Nisalak, and F. A. Ennis. 1997. Early clinical and laboratory indicators of acute dengue illness. J. Infect. Dis. 176:313-321.
20. Katoka, T., N. Shinohara, H. Takayama, K. Takaku, S. Kondo, S. Yonehara, and K. Nagai. 1996. Concanamycin A, a powerful tool for characterization and estimation of contribution of perforin-and Fas-based lytic pathways in cell-mediated cytotoxicity. J. Immunol. 156:3678-3686.
21. Kerr, J. F., W. G. Cooksley, J. Searle, J. W. Halliday, W. J. Halliday, I. Holder, I. Roberts, W. Burnett, and L. W. Powell. 1979. The nature of piecemeal necrosis in chronic active hepatitis. Lancet 11:827-828.
22. Knowles, B. B., C. C. Howe, and D. P. Aden. 1980. Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen. Science 209:479-499.
23. Kuno, G., and R. E. Bailey. 1994. Cytokine responses to dengue infection among Puerto Rican patients. Mem. Inst. Oswaldo Cruz 89:179-182.
24. Kuo, C., D. Tai, C. Chang-Chien, C. Lan, S. Chiou, and Y. Liaw. 1992. Liver biochemical tests and dengue fever. Am. J. Trop. Med. Hyg. 47:265-270.
25. Kurane, I., B. L. Innis, C. Nisalak, C. Hoke, S. Nimmanitya, A. Meager, and F. A. Ennis. 1989. Human responses to dengue virus antigens. Proliferative responses and interferon gamma production. J. Clin. Invest. 83:505-513.
26. Kurane, I., A. Meager, and F. A. Ennis. 1989. Dengue virus-specific human T cell clones: serotype crossreactive proliferation, interferon-γ production, and cytotoxic activity. J. Exp. Med. 170:763-775.
27. Kurane, I., B. L. Innis, S. Nimmannitya, A. Nisalak, A. Meager, J. Janus, and F. A. Ennis. 1991. Activation of T lymphocytes in dengue virus infections. High levels of soluble interleukin 2 receptor, soluble CD4, soluble CD8, interleukin 2, and Interferon-γ in sera of children with dengue. J. Clin. Invest. 88:1473-1480.
28. Kurane, I., and F. A. Ennis. 1994. Cytotoxic T lymphocytes in dengue virus infection. Curr. Top. Microbiol. Immunol. 189:93-105.
29. Lacronique, V., A. Mignon, M. Fabre, B. Viollet, N. Rouquet, T. Molina, A. Porteu, A. Henrion, D. Bouscary, P. Varlet, V. Joulin, and A. Kahn. 1996. Bcl-2 protects from lethal hepatic apoptosis induced by an anti-Fas antibody in mice. Nat. Med. 2:80-86.
30. Leithauser, F., J. Dhein, G. Mechtersheimer, K. Koretz, S. Bruderlein, C. Henne, A. Schmidt, K.-M. Debatin, P. H. Krammer, and P. Moller. 1993. Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab. Invest. 69:415-429.
31. + T cells use both CD95-dependent and CD95-independent cytolytic mechanisms. J. Immunol. 160:2374-2379.
32. + human CTL clones induced by candidate AIDS vaccines. J. Immunol. 153:2787-2799.
33. Mori, M., I. Kurane, J. Janus, and F. A. Ennis. 1997. Cytokine production by dengue virus antigen-responsive human T lymphocytes in vitro examined using a double immunocytochemical technique. J. Leukocyte Biol. 61:338-345.
34. + T lymphocytes possessing cytolytic activity confer protection in the absence of prophylactic antibodies. J. Virol. 69:4914-4923.
35. Nimmannitya, S. 1987. Clinical spectrum and management of dengue haemorrhagic fever. Southeast Asian J. Trop. Med. Public Health 18:392-397.
36. + human cytolytic T cells specific for HIV-infected cells by a gp120 subunit vaccine. Science 248: 1234-1237.
37. Ramsdell, F., M. S. Seaman, R. E. Miller, K. S. Picha, M. K. Kennedy, and D. H. Lynch. 1994. Differential ability of Th1 and Th2 T cells to undergo activation-induced cell death. Int. Immunol. 6:1545-1553.
38. Sabin, A. B. 1952. Research on dengue during World War II. Am. J. Trop. Med. Hyg. 1:30-50.
39. Sherman, M. L., D. R. Spriggs, K. A. Arthur, K. Imamura, E. I. Frei, and D. W. Kufe. 1988. Recombinant human tumor necrosis factor administered as a five-day continuous infusion in cancer patients: phase I toxicity and effects on lipid metabolism. J. Clin. Oncol. 6:344-350.
40. Smyth, M. J. 1997. Fas Ligand-mediated bystander lysis of syngeneic cells in response to an allogeneic stimulus. J. Immunol. 158:5765-5772.
41. Spriggs, D. R., M. L. Sherman, H. Michie, K. A. Arthur, K. Imamura, D. Wilmore, E. I. Frei, and D. W. Kufe. 1988. Recombinant human tumor necrosis factor administered as a 24-hour intravenous infusion. A phase I and pharmacologic study. J. Nat. Cancer Inst. 80:1039-1044.
42. + T cell-mediated cytotoxicity. J. Immunol. 152:1127-1133.
43. Van Voorhis, W. C., L. K. Barren, J. M. Nasio, F. A. Plummer, and S. A. Lukehart. 1996. Lesions of primary and secondary syphilis contain activated cytolytic T cells. Infect. Immun. 64:1048-1050.
44. + T cell clones use perform-or Fas/Fas ligand-mediated pathways for target cell lysis. J. Immunol. 158:2756-2761.
45. Vitarana, T., H. de Silva, N. Withana, and C. Gunasekera. 1991. Elevated tumour necrosis factor in dengue fever and dengue haemorrhagic fever. Ceylon Med. J. 36:63-65.
46. + cytotoxic T cells in recovery from mouse hepatitis virus infection. Immunology 87:34-41.
47. Woo, J.-T., C. Shinohara, K. Sakai, K. Hasumi, and A. Endo. 1992. Isolation, characterization, and biological activities of concanamycins as inhibitors of lysosomal acidification. J. Antibiot. 45:1108.
48. Yadav, M., K. R. Kamath, N. Iyngkaran, and M. Sinniah. 1991. Dengue haemorrhagic fever and dengue shock syndrome: are they tumour necrosis factor-mediated disorders? FEMS Microbiol. Immunol. 89:45-50.
49. - herpes simplex virus-specific human cytotoxic T cells. J. Immunol. 143:2051-2057.
50. + human cytotoxic T cell clones. Clin. Immunol. Immunopathol. 78:70-76.